Biotechnology & Life Sciences Global On demand · 24-48h

Global Nanopore Molecular Sequencing Service Market Strategic Research Report

Global Nanopore Molecular Sequencing Service Market Strategi…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Nanopore Molecular Sequencing Service Market
$3382025
9.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Direct DNA Sequencing, Direct RNA Sequencing, cDNA Sequencing (RNA→cDNA), DNA+RNA Combined Sequencing

By Application: Life Sciences, Clinical Medicine, Biomedicine, Public Health, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Azenta Life Sciences, Novogene Co., Ltd., BGI Genomics Co., Ltd., Eurofins Genomics, Plasmidsaurus, Biomarker Technologies Corporation, Macrogen Inc., CD Genomics, Microsynth AG, BaseClear, Genotypic Technology Pvt. Ltd., Takara Bio Inc., FASMAC Co., Ltd., SeqCenter, SeqCoast Genomics, Wuhan Benagen Tech Co., Ltd., GenoScreen, IGA Technology, MicrobesNG, Source BioScience, GenXone, PathoSense, AllGenetics, BIOTOOLS Co., Ltd., GeneBay, Inc., Seibutsugiken Co., Ltd., Biofidus, KeyGene, LongSeq Applications

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 166 pages
Market size 2025
$338
Million USD
Forecast CAGR
9.1%
2025-2032
Forecast 2032
$621.9
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global Nanopore Molecular Sequencing Service market size is predicted to grow from US$ 338 million in 2025 to US$ 618 million in 2032; it is expected to grow at a CAGR of 9.1% from 2026 to 2032.

Nanopore sequencing services refer to professional services provided by third-party genomics service providers, research sequencing platforms, CRO laboratories, or core laboratories with external service capabilities. These services utilize nanopore sequencing technology to perform sample quality control, nucleic acid extraction, library construction, sequencing, real-time signal acquisition, base identification, quality control, bioinformatics analysis, and result delivery for DNA, RNA, and related nucleic acid samples. This research focuses on paid sequencing services used in scientific research, clinical research, biopharmaceutical quality control, agricultural genomics, environmental monitoring, pathogen identification, synthetic biology, and population genomics. The core technology of nanopore sequencing services utilizes nanopore channels to detect changes in current caused by the passage of individual nucleic acid molecules, enabling long read lengths, ultra-long read lengths, real-time sequencing, direct DNA/RNA sequencing, and partial base modification identification. Typical service formats include nanopore whole-genome sequencing, full-length transcriptome sequencing, direct RNA sequencing, methylation sequencing, metagenomic sequencing, targeted sequencing, amplicon sequencing, whole plasmid sequencing, AAV genome sequencing, and corresponding bioinformatics analysis.

Nanopore molecular sequencing services were becoming increasingly popular and gaining traction in the genomics and biotechnology fields. Nanopore sequencing is a technology that allows direct, real-time sequencing of DNA and RNA molecules. It offers several advantages over traditional sequencing methods, such as long read lengths, portability, and the ability to sequence native DNA without amplification. Nanopore sequencing services were experiencing a growing demand due to their applications in various fields, including genomics research, clinical diagnostics, agriculture, and environmental monitoring. Ongoing research and development efforts were leading to improvements in nanopore sequencing technology, enhancing accuracy and reducing costs, making it more attractive for broader adoption.

This report presents a comprehensive overview of the global Nanopore Molecular Sequencing Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Direct DNA Sequencing
  • Direct RNA Sequencing
  • cDNA Sequencing (RNA→cDNA)
  • DNA+RNA Combined Sequencing

Segment by Nanopore Count

  • 512~2,048 wells
  • 2,560 wells
  • 144,000 wells

Segment by Service Mode

  • Dry Rental
  • Wet Rental
  • Data as a Service (DaaS)

Segment by Application

  • Life Sciences
  • Clinical Medicine
  • Biomedicine
  • Public Health
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Nanopore Molecular Sequencing Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Life Sciences, Clinical Medicine, Biomedicine evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Nanopore Molecular Sequencing Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 9.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$338
2025
Forecast
$621.9
2032
CAGR
9.1%
2025–2032
Regions
5
global
Key companies
Azenta Life SciencesNovogene Co., Ltd.BGI Genomics Co., Ltd.Eurofins GenomicsPlasmidsaurusBiomarker Technologies CorporationMacrogen Inc.CD Genomics
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Direct DNA SequencingDirect RNA SequencingcDNA Sequencing (RNA→cDNA)DNA+RNA Combined Sequencing
By Application
Life SciencesClinical MedicineBiomedicinePublic HealthOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Direct DNA Sequencing
  • 3.1.3 Direct RNA Sequencing
  • 3.1.4 cDNA Sequencing (RNA→cDNA)
  • 3.1.5 DNA+RNA Combined Sequencing
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Life Sciences
  • 4.1.3 Clinical Medicine
  • 4.1.4 Biomedicine
  • 4.1.5 Public Health
  • 4.1.6 Other
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Azenta Life Sciences
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Novogene Co., Ltd.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 BGI Genomics Co., Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Eurofins Genomics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Plasmidsaurus
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Biomarker Technologies Corporation
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Macrogen Inc.
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 CD Genomics
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Microsynth AG
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 BaseClear
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Genotypic Technology Pvt. Ltd.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Takara Bio Inc.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 FASMAC Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 SeqCenter
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 SeqCoast Genomics
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Wuhan Benagen Tech Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 GenoScreen
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 IGA Technology
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 MicrobesNG
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Source BioScience
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 GenXone
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 PathoSense
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 AllGenetics
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 BIOTOOLS Co., Ltd.
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 GeneBay, Inc.
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Seibutsugiken Co., Ltd.
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Biofidus
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 KeyGene
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 LongSeq Applications
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Nanopore Molecular Sequencing Service market size?
The global Nanopore Molecular Sequencing Service market is estimated at US$ 338 million in 2025 (base year) and is projected to reach US$ 618 million by 2032.
What growth rate is expected for the Nanopore Molecular Sequencing Service market through 2032?
The market is expected to grow at a CAGR of 9.1% from 2026 to 2032, expanding from US$ 338 million in 2025 to US$ 618 million in 2032, roughly 1.8 times its base-year value.
How is Nanopore Molecular Sequencing Service defined?
Nanopore sequencing services refer to professional services provided by third-party genomics service providers, research sequencing platforms, CRO laboratories, or core laboratories with external service capabilities. These services utilize nanopore sequencing technology to perform sample quality control, nucleic acid extraction, library construction, sequencing, real-time signal acquisition, base identification, quality control, bioinformatics analysis, and result delivery for DNA, RNA, and related nucleic acid samples.
What are the main segments of the Nanopore Molecular Sequencing Service market by type?
By type, the market is segmented into Direct DNA Sequencing, Direct RNA Sequencing, cDNA Sequencing (RNA→cDNA) and DNA+RNA Combined Sequencing.
Which applications drive demand in the Nanopore Molecular Sequencing Service market?
Key applications covered include Life Sciences, Clinical Medicine, Biomedicine, Public Health and Other.
Who are the key players in the Nanopore Molecular Sequencing Service market?
Key players profiled include Azenta Life Sciences, Novogene Co., BGI Genomics Co., Eurofins Genomics, Plasmidsaurus, Biomarker Technologies Corporation, Macrogen Inc. and CD Genomics, among 29 companies covered in total.
Which regions and countries are covered for Nanopore Molecular Sequencing Service?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Nanopore Molecular Sequencing Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Life Sciences, Clinical Medicine and Biomedicine, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Nanopore Molecular Sequencing Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.